From the Research
There is no recommended starting dose of THC for pediatric patients, as THC is not approved for use in children or adolescents due to potential risks to brain development and long-term cognitive effects. The use of THC in pediatric patients is strongly advised against by medical professionals, as the developing brain is particularly vulnerable to the effects of THC, which can negatively impact memory, learning, and cognitive function in young people 1, 2. In extremely rare cases where a physician might consider cannabinoids for a pediatric patient with a severe condition, they would likely use CBD (cannabidiol) products that contain little to no THC, with any such use being closely monitored and only under direct medical supervision.
Some studies have investigated the disposition of oral THC in children, but these have significant limitations and do not provide a basis for recommending a starting dose for pediatric patients 3. Other research has proposed standardizing THC units to guide consumers and promote safer patterns of use, but this does not apply to pediatric patients due to the risks associated with THC exposure 4.
If a parent is considering cannabis-based treatments for a child's medical condition, they should consult with a pediatric specialist to discuss evidence-based, age-appropriate options that do not involve THC exposure. The primary concern in pediatric medicine is to prioritize the health, safety, and well-being of children, and the use of THC is not supported by current evidence as a safe or effective treatment for pediatric patients.
Key considerations for pediatric patients include:
- The potential risks of THC exposure to brain development and cognitive function
- The lack of approved THC products for pediatric use
- The need for close monitoring and medical supervision in cases where cannabinoids are considered for pediatric patients
- The importance of consulting with a pediatric specialist to discuss evidence-based treatment options that do not involve THC exposure.